Key Takeaways Nausea is one of the most common side effects of GLP-1 medications and is usually most noticeable when starting treatment or increasing your dose
For example, a 150 pound person should ideally be consuming at least 81 grams of protein per day
Compound: Retatrutide Format: Lyophilized peptide research vial Available Strengths: 10MG, 20MG, and 30MG Research Category: GLP-1 / GIP / glucagon triple agonist peptide research Research Focus: Incretin biology, metabolic regulation, GLP-1 receptor pathway research, GIP receptor signaling, glucagon receptor models, substrate utilization, energy-balance biology, and appetite-associated pathway research
The earliest expected NDA filing with the FDA is Q4 2026, which would put a realistic FDA decision in 2027 or later
Two separate charges
Their evaluation of the effect of GLP-1 was also aided by their access to RIAs for GLP-1 (Holst 2024)